Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

Apabetalone (RVX-208) is an epigenetic regulator developed to treat cardiovascular disease (CVD) that targets BET proteins. Through transcriptional regulation RVX-208 modulates pathways that underlie CVD including reverse cholesterol transport, vascular inflammation, coagulation, and complement. Usi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Cardiovasc Transl Res
Glavni autori: Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Calosing, Cyrus, Jahagirdar, Ravi, Johansson, Jan, Sweeney, Michael, Wong, Norman C., Kulikowski, Ewelina
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2017
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5585290/
https://ncbi.nlm.nih.gov/pubmed/28567671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12265-017-9755-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items